Research and Markets: The Indian Contract Manufacturing Market is Expected to Grow...

Research and Markets: The Indian Contract Manufacturing Market is Expected to Grow in Excess of CAGR 37% Between 2007 and 2012

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reports/c86547) has announced the
addition of Indian Contract Manufacturing -- A Hot Opportunity to
their offering.

"Indian Contract Manufacturing -- A Hot Opportunity" is the recent
report that gives first hand information on the thriving contract
manufacturing market in India and the opportunities it is opening up
for global players.

The Indian contract manufacturing market was worth US$ 874 Million
in 2007. Although this market presently occupies a fraction of the
total global opportunity, the future potential of the market seems
immense. The Indian contract manufacturing market, with its low cost
advantage, strong chemistry and reverse engineering capabilities,
improving infrastructure and strong incentives from the government, is
expected to grow strongly in the next five years. By 2012, the Indian
industry is expected to grab nearly 8% of the total global market.

The report comprehensively evaluates the contract manufacturing
market in India, analyzing its present market size, key segments,
capabilities, and the future direction of growth. It also gives a
statistical and analytical insight into the various factors vital for
drug manufacturing, such as the competitive advantage/disadvantage of
India vis-a-vis developed countries on various parameters such as
cost, infrastructure, intellectual property and infrastructure etc.

Key Findings

-- Indian contract manufacturing market is expected to grow in
excess of CAGR 37% between 2007 and 2012.

-- Most companies presently outsource APIs and intermediates from
India. Moreover, India is also becoming a major hub for outsourcing
formulations.

-- Many Indian manufacturers have upgraded their manufacturing
plants, which has enabled India to have a number of plants certified
by the FDA, EDQM and various other regulatory agencies.

-- The cost of secondary manufacturing in India is around 13%-15%
of the cost in the US, the UK and Germany, with companies making
substantial savings on costs of plant set up, labor and operations.

-- India has more than four times the total drug manufacturing
staff than the US and more than 12 times that in the UK.

-- Growth of the contract manufacturing market is expected to
provide a major boost to the pharma machinery market in India, which
is expected to register revenues up to US$ 822 Million by 2010.

-- Strong appreciation of the Indian Rupee against the US Dollar
is having a detrimental effect on the profits of many Indian contract
manufacturers.

Key Issues & Facts Analyzed

-- Evaluation of the total size and growth rate of the contract
manufacturing market.

-- Analysis of key segments.

-- Evaluation of India's capability in pharmaceutical
manufacturing.

-- Analysis of the total costs incurred while manufacturing a drug
in India (such as cost of land, construction, labor, utilities,
freight etc).

-- Analysis of the country's pharma-related human resources.

-- Study of the country's pharma-related infrastructure.

-- Analysis of the key opportunities created by the industry.

-- Analysis of key players, including their business overview, key
facts, and financial information.

Research Methodology Used

Information Sources

Information has been sourced from books, newspapers, trade
journals, and white papers, industry portals, government agencies,
trade associations, monitoring industry news and developments, and
through access to more than 3000 paid databases.

Analysis Methods

The analysis methods include ratio analysis, historical trend
analysis, linear regression analysis using software tools, judgmental
forecasting and cause and effect analysis.

-0-
*T
Companies Mentioned:
-- Divis Laboratories Limited
-- Dr. Reddy's Laboratories Limited
-- Nicholas Piramal India Limited
-- Jubilant Organosys Healthcare Limited
-- Shasun Chemicals and Drugs Limited
-- Dishman Pharmaceuticals & Chemicals Limited
*T

For more information visit
here.

Research and Markets Ltd.
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax: +353 1 4100 980

Copyright Business Wire 2008